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Abstract
Background: Single Nucleotide Polymorphisms (SNPs) in intron 2 of the Fibroblast Growth Factor Receptor Type 2
(FGFR2) gene, including rs2981582, contribute to multifactorial breast cancer susceptibility. The high risk
polymorphism haplotype in the FGFR2 gene has been associated with increased mRNA transcription and altered
transcription factor binding but the effect on FGFR2 protein expression is unknown. 40 breast tumours were
identified from individuals with known rs2981582 genotype. Tumour sections were stained for FGFR2 protein
expression, and scored for nuclear and cytoplasmic staining in tumour and surrounding normal tissue.
Findings: FGFR2 immunohistochemistry demonstrated variable nuclear staining in normal tissue and tumour tissue,
as well as consistent cytoplasmic staining. We did not find an association between nuclear staining for FGFR2 and
genotype, and there was no association between FGFR2 staining and estrogen or progestogen receptor status.
There was an association between presence of nuclear staining for FGFR2 in normal tissue and presence of nuclear
staining in the adjacent tumour (Fishers exact test, p = 0.002).
Conclusions: Variable nuclear staining for FGFR2 in breast cancer, but an absence of correlation with rs2981582
genotype suggests that the mechanism of action of polymorphisms at the FGFR2 locus may be more complex
than a direct effect on mRNA expression levels in the final cancer. The effect may relate to FGFR2 function or
localisation during breast development or tumourigenesis. Nuclear localisation of FGFR2 suggests an important
additional role for this protein in breast development and breast cancer, in addition to its function as a classical
cell surface receptor.
Background
Fibroblast growth factor receptor type 2 (FGFR2) is a
receptor tyrosine kinase involved in a number of cell
signalling pathways that contribute to cell growth and
differentiation [1]. FGFR2 is important in development
of a number of tissues including breast and kidney [2,3].
Mutations in FGFR2 can also cause rare monogenic dis-
eases such as lacrimo-auriculo-dento-digital (LADD)
syndrome and syndromic craniosynostosis [4]. However,
recent interest has focussed on Single Nucleotide Poly-
morphisms (SNPs) in intron 2 of FGFR2 ,i n c l u d i n g
rs2981582, which form a high risk haplotype that is
associated with an increased risk of breast cancer [5,6].
The risk haplotype in FGFR2 is associated with both
oestrogen receptor positive (ER+ve) and ER-ve tumours,
although the association with ER+ve tumours is
stronger.
Although principally considered a cell surface recep-
tor, FGFR2 is also found to have nuclear localisation in
a number of different breast and cancer related contexts
[7,8]. The related receptor FGFR1 has been shown to be
transported actively to the nucleus, where it may act as
a transcription factor coordinating gene expression and
promoting cellular differentiation [9]. FGFR2 has also
been has been identified in the terminal end buds dur-
ing mammary gland development, with nuclear localisa-
tion [8], suggesting that the nuclear localisation plays an
important role in breast development.
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breast cancer, and association of polymorphisms in
FGFR2 with breast cancer [5,6], the mechanism by
which these polymorphisms predispose to breast cancer
remains uncertain. Previous analysis of polymorphisms
in the FGFR2 linkage disequilibrium block including
rs2981582 has identified a putative oestrogen receptor
binding site and a further polymorphism in a POU tran-
scription factor binding domain [5]. One study has
investigated the effect of FGFR2 genotype on transcrip-
tion factor binding and mRNA production [10]. This
study demonstrated that the high risk SNP haplotype
has higher affinity for the transcription factor RUNX2.
However, analysis and quantification of the FGFR2 tran-
script did not show any variation in splicing with geno-
type, but suggested increased transcription of FGFR2
from the minor (increased risk) haplotype.
Further investigation of the FGFR2 gene region has
suggested that the effect on RUNX2 binding is caused
by the polymorphism rs2981578. Other polymorphisms
in the same linkage disequilibrium block have been sug-
gested as having an effect on binding of other transcrip-
tion factors, including rs7895676 which is located in a
C/EBPb binding site [5,11]. One of the effects of poly-
morphisms in the linkage disequilibrium block appears
to be alteration local histone acetylation in breast cancer
cell lines [12]. It remains unclear as to whether a single
polymorphism is responsible, or the effect is caused by
several polymorphisms in cis acting together.
Several studies investigating expression of FGFR2 pro-
tein in breast cancer seem to contradict the hypothesis
that overexpression of FGFR2 is a step in tumour devel-
opment. Early studies have shown expression of FGFR2
only in a minority (4% and 12%) of breast cancers
[13,14]. A more recent study using a combination of dif-
ferent techniques to investigate gene expression, protein
levels and genomic changes involving FGFR2 in breast
cancer suggested that FGFR2 levels are lower in tumour
tissue than the adjacent normal breast ducts, and that in
a proportion of cases, this could be attributed to LOH
or methylation involving the FGFR2 locus [12]. This
study did not investigate whether genotype itself had an
effect on gene and protein expression.
In order to further investigate the role of FGFR2
expression in breast cancer, and whether protein expres-
sion and sub-cellular localisation in tumour correlated
with genotype in patients, we used immunohistochemis-
try to examine FGFR2 expression and localisation in
cancers from individuals of known rs2981582 genotype.
Materials and methods
40 invasive (ductal) carcinomas of no special type were
chosen for availability of material for staining, compar-
able grade, ER, progesterone receptor and HER2
receptor status. Patients were selected as homozygous
for the low risk (G) allele (16 patients), heterozygous
(A/G) (10 patients), or homozygous for the high risk (A)
allele (14 patients). Patient genotype was determined
using blood from peripheral blood leucocytes. Ethical
approval was obtained through the ethics committee of
the Tayside Tissue Bank.
Genotyping of samples had previously carried out
using pre-designed Taqman SNP genotyping assays pur-
chased from Applied Biosystems™, carried out accord-
ing to manufacturer’sg u i d e l i n e sa n da n a l y s e di na9 6
well or 384 well format using an ABI 7700™.
Immunohistochemistry was carried out on formalin
fixed, paraffin embedded breast cancer tissue. 4 micron
sections were placed onto positively charged slides
(BDH Lab systems), incubated for 1 hour at 60°C, de-
waxed and re-hydrated prior to microwave antigen
retrieval in citric acid buffer (citric acid, 10 mM, pH6.4)
for 15 minutes. FGFR2 expression was detected using a
rabbit polyclonal anti-FGFR2 antibody (C-17-SC122;
Santa Cruz). Negative controls were carried out by
omitting the primary antibody. Positive controls
included normal skin and a dermatofibroma. Prior to
antibody binding, a manual avidin and biotin blocking
step was carried out to reduce background. Immunohis-
tochemistry was performed using a TECHMATE™500
autostainer (DAKO). Slides were labelled with the pri-
mary antibody (at 1:50 concentration) (1 hr), followed
by detection with biotinylated secondary antibody
(25 minutes) and streptavidin peroxidase (25 minutes),
with peroxidase staining using a solution containing
DAB, HRP-substrate buffer and the substrate working
solution CHROM (3 × 5 minutes) with wash steps
between. Cells were counterstained with haematoxylin
and images captured by our Virtual Microscopy (VM)
apparatus (Aperio ScanScope XT™, Aperio Technolo-
gies), at a x40 objective and archived within the ‘Aperio
Spectrum Plus + TMA’ database (version 9.0.748.1521).
Immunohistochemical staining was reviewed in detail
a n ds c o r e db yas i n g l ee x p e r i enced breast pathologist
(LBJ) who was blinded to tumour genotype and the
scoring was conducted in isolation and in the absence
of any other data. A second, blinded, review and opinion
by another experienced breast pathologist (CAP) was
conducted for corroboration purposes. All staining was
checked both using images generated by the Aperio
ScanScope™and optically using a Nikon Eclipse E600
microscope.
Initially, invasive malignancy was scored. Subse-
quently, where present on the original slide, normal
breast epithelium was also scored, with additional quali-
tative comments made on other regions of interest in
the slide. Antibody staining was assessed and scored
using the “Quick Score method” [15]. Briefly, the
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score on a scale of 1 to 6; 0 - 4% = 1, 5 - 19% = 2, 20 -
39% = 3, 40 - 59% = 4, 60 - 79, and 80 - 100% = 6. The
average intensity of the positively staining cells was esti-
mated and given a score of 0 to 3; no staining = 0, weak
staining = 1, intermediate staining = 2, and strong stain-
ing = 3. The Quick Score was then calculated by multi-
plying the percentage of cells staining score by the
intensity score to give a maximum value of 18. In addi-
tion, the cellular localisation of the antibody staining
was noted to be both nuclear and cytoplasmic, and
therefore both compartments were scored. No mem-
brane specific staining was present. This score was used
for all subsequent analyses.
Data was stored on an Excel™spreadsheet, and ana-
lysed by construction of 2 × 2 and 3 × 2 contingency
tables, using Fishers exact test, the Chi Square test or Chi
square test for trend as appropriate, using OpenEpi 2.2.1.
There is no agreed threshold for scoring FGFR2 stain-
ing by immunohistochemistry. For all comparisons with
staining, we analysed our data twice, once using a
grouping of no staining against any staining (score 0 or
greater than 0), and secondly using a cutoff of 0-3 or
greater than 3, the same criteria used for estrogen
receptor positivity.
Immunohistochemical staining was available on all 40
tumours, but only for 29 normal tissues present in the
same slide. For comparisons of tumour with normal tis-
sue, we performed the analysis twice, once using just
the 29 tumours with associated normal tissue, and sub-
sequently comparing staining levels in all 40 tumours
against all 29 normal tissues.
Results
Examples of the different patterns of cytoplasmic and
nuclear staining for FGFR2 that we observed in malig-
nancies and normal tissue are shown in Figures 1 and 2.
All except one tumour (which had a G/G genotype)
showed faint generalised cytoplasmic staining, which
was not confined to the membrane. Therefore, no signif-
icant association of genotype with cytoplasmic staining
was demonstrated.
More notably, a proportion of tumours showed defi-
nite nuclear staining for FGFR2. We therefore compared
rs2981582 genotype with nuclear staining for protein.
No significant difference was observed in FGFR2 stain-
ing between patients with different genotypes at this
locus, either using a cut off score of 0, or using a cut off
s c o r eo f4( t h es a m es c o r et h a tw o u l db eu s e dt oa s s e s s
oestrogen receptor positivity). These data are shown in
table 1 and Figure 3.
The normal background breast epithelium (ductal
and lobular) could be analysed in 29 cases. Normal
epithelium displayed similar cytoplasmic staining,
scoring between 3 and 6 in all cases examined. This
normal epithelium also displayed variable, often weak
and scattered nuclear staining. Stronger nuclear
staining was noted in some hyperplastic regions and
in areas displaying columnar cell features. No signifi-
cant difference in FGFR2 staining of normal tissue
was observed with rs2981582 genotype, shown in
table 2.
Analysis of FGFR2 nuclear staining in relation to oes-
trogen receptor and progesterone receptor status did
not show any significant correlation, shown in table 3.
We noted that the nuclear staining scores for tumours
were sometimes higher than those for the adjacent nor-
mal tissue. Analysis of this using a cut-off of less than 4
against a score of 4 or greater suggested that tumours
were more likely to show significant nuclear expression
of FGFR2 than the surrounding tissue, shown in table 4.
This result was marginally significant if we only included
tumour from the 29 slides where normal tissue was also
present. The significance level was higher if we combined
t h ed a t at op e r f o r mac o m p a r i s o no fs t a i n i n go fa l l4 0
tumours and the staining of 29 areas of normal tissue.
Figure 1 FGFR2 staining in 3 different intraductal breast cancers of no specific type (all at 20X objective). 1A showing occasional nuclear
staining. 1B showing prominent staining of all nuclei. 1C showing moderate cytoplasmic staining.
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mal tissue and tumour tissue for each slide where both
were present. This, shown in table 5, showed that in all
except one case, where nuclear staining was present at
any level in normal tissue, it was present in adjacent
tumour. In 5/15 cases, staining was seen in tumour
where it was not seen in adjacent normal tissue (p =
0.002, Fishers exact test). This suggests that FGFR2
expression and localisation in tumour tends to reflect
the expression and localisation in the background tissue
it arises from. However, tumorigenesis may be more
likely to increase FGFR2 expression above the back-
ground than decrease it.
Whilst the nuclear staining was quite dramatic, parti-
cularly within certain invasive tumours, consideration
has been given to the possiblility that the cytoplasmic
staining may be a background artefact of this antibody
clone, however, it is variable in distribution and intensity
and therefore expected to represent actual expression.
The nuclear staining for FGFR1 and FGFR2 seen in this
and other studies suggests that nuclear staining is a gen-
uine finding for FGFR proteins.
Discussion
While increased levels of FGFR2 transcript have been
observed previously in patients who are homozygous for
the rare rs2981582 allele [10], we were unable to
demonstrate an increase in cytoplasmic protein levels by
immunohistochemistry. Although nuclear expression of
FGFR2 might represent increased expression of protein,
there are other explanations, including altered cellular
localisation of the existing protein in the cell. Whichever
is the case, no clear correlation with rs2981582 genotype
was observed.
The FGFR2 mRNA may be unstable, and degraded
before translation, so that increased levels do not lead to
increased protein production. However, in this case it
would be difficult to explain how increased mRNA pro-
duction would lead to an increased risk of cancer.
Our sample size is comparatively small. For a highly
variable cellular phenotype such as protein expression, it
is possible that analysis of a larger cohort would reveal a
subtle correlation that we were not able to detect.
It is, as yet, uncertain which polymorphism is genu-
inely responsible for the increased risk, or whether
Figure 2 FGFR2 expression in non-malignant breast epithelium. Both using 20X objective. 2A showing some nuclear staining in epithelial
cells in breast lobule. 2B showing more prominent nuclear staining and some cytoplasmic staining in breast epithelium showing columnar cell
features.
Table 1 Breast Tumour Staining for FGFR2 by Patient Genotype
rs2981582 genotype Nuclear Score 0 Nuclear Score
>0
Nuclear Score
0-3
Nuclear Score
4+
GG 4 12 12 4
G A 3 764
A A 5 995
c
2 for trend = 0.19, ns c
2 for trend = 0.69, ns
A comparison of tumour staining scores by patient genotype. Scores are compared for the 40 tumour samples. No significant difference in staining was found by
genotype. The raw data for this analysis is shown in a dot plot in Figure 3.
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with other polymorphisms in FGFR2 might demonstrate
a better correlation with protein expression. However,
rs2981582 is within the linkage disequilibrium block
that confers risk and has originally been shown to corre-
late with mRNA expression [10].
FGFR2 is involved in breast development [8], so
increased FGFR2 expression may be an early event in
embryonic development or childhood that sets the scene
for a higher risk of breast cancer in later life without
being involved directly in tumour behaviour in the
adult. Breast epithelial cells with an increased risk
FGFR2 genotype may be primed to respond differently
to growth factors and endocrine influences. Alternatively
there may be significant variation in levels of FGFR2 in
mature breast, below that detectable by immunohisto-
chemistry. The variation in FGFR2 expression that is
responsible for risk may be in a small subpopulation of
cells (for example the stem cell precursors), that would
not be apparent on conventional viewing of stained sec-
tions. It is also possible that the effect of FGFR2 protein
expression is mediated by another cell type, such as
fibroblasts, affecting the tumour cell microenvironment,
not the tumour cells themselves.
In mammary epithelial cells, the specificity of pathway
activation by FGFR2 may be dependent on the balance of
the different splice forms of this gene [16,17]. The causa-
tive polymorphism in FGFR2 may affect FGFR2 splicing,
leading to splice forms that may behave differently in
terms of signalling activation or cellular localisation, but
which stain similarly by immunohistochemistry.
Although marked overexpression of FGFR2 has pre-
viously been reported in up to 12% of breast tumours
[13,14], we did not observe this phenomenon in the 40
tumours that we analysed. We did not, therefore, find
any evidence that overexpression of FGFR2 was related
to genotype. If overexpression of FGFR2 in breast can-
cer was related to genotype, it is doubtful whether over-
expression of FGFR2 in 12% of tumours, even if only
possible on a high risk allele background, would in itself,
account for the increase in clinical risk in breast cancer.
One mechanism for over-expression of FGFR2 would be
increase in copy number of FGFR2 in tumours. We did
not assess this, but the absence of correlation between
protein expression and patient constitutional genotype
suggests that likelihood of FGFR2 gene amplification is
not strongly related to patient genotype at the locus.
Nuclear staining for FGFR2 and its importance in
human breast cancer has been highlighted by this study.
This nuclear expression was variable but more promi-
nent in certain tumours. This has not previously been
investigated in human breast cancers, or considered in
relation to genotype. The nuclear localisation of FGFR2
raises important questions about the function of the
receptor and, hence, the potential mechanism of action
of polymorphisms in the gene.
Nuclear expression of FGFR2 has been observed pre-
viously in normal mouse breast development and lung
tumours [18], as well as mouse mammary gland [8] but
not human breast cancer. It seems likely that FGFR2
has a similar, unusual, mechanism of receptor action to
FGFR1 [9] which has been shown to localise to the
nucleus in some situations, possibly promoting cell dif-
ferentiation. The nuclear signalling by FGFR2 may,
therefore, contribute to a protective mechanism against
cancer. It would be important to consider this when
designing new breast cancer treatments that target the
Figure 3 Dot plots showing distribution of nuclear staining by
genotype. Figure 3A shows results for nuclear staining in tumour
and figure 3B shows results for nuclear staining in normal tissue.
Table 2 Staining for FGFR2 in Normal Breast Tissue
rs2981582 genotype Nuclear Score 0 Nuclear Score
>0
Nuclear Score
0-3
Nuclear Score
4+
GG 6 4 10 0
G A 4 590
A A 5 591
c
2 for trend = 0.48, ns c
2 for trend not calculated
Staining for FGFR2 in normal tissue where it was present in the same section as tumour. This analysis was possible in 29 samples. No significant difference in
staining was found by genotype. The raw data for this analysis is shown in a dot plot in Figure 3.
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therefore, be expected to have the wrong effect on dis-
ease progression.
The association between tumour nuclear FGFR2
expression and expression in the original normal tissue
is interesting, as it suggests that the level of FGFR2
expression may be programmed into the normal tissue
in advance of the cancer developing. As the tissue we
examined was on the same slide as the tumour, this
may be a regional phenomenon, and a step in tumori-
genesis in the breast. Alternatively nuclear FGFR2
expression may be an innate general characteristic of
the breast tissue in some individuals, but not others.
The factors that control this expression phenotype are
therefore interesting in understanding how the control
of FGFR2 expression relates to tumour formation and
genotype.
There is a disparity between our data, and that of Zhu
et al. [12]. We do not see any evidence of down regula-
tion of FGFR2 compared to normal tissue. In addition,
we did not see the increase in protein with genotype
that might be expected from the data presented by
Meyer [10], where increased transcription was seen with
the risk genotype, However, as discussed above, there
are a number of reasons why increased mRNA expres-
sion may not translate into increased protein seen on
immunohistochemical staining. Further work is required
to establish the effect of FGFR2 polymorphisms on gene
function.
Our findings, including the nuclear localisation of
FGFR2 and the lack of effect of FGFR2 genotype at
rs2981582 on cytoplasmic expression, are important
Table 4 Nuclear FGFR2 Staining in Breast Tumours compared to Normal Tissue
Nuclear Score
0
Nuclear Score
>0
Nuclear Score
0-3
Nuclear Score
4+
Normal Tissue 15 14 28 1
Tumour
(normal present)
11 18 22 7
p = 0.43 (Fishers Exact Test) p = 0.05 (Fishers Exact Test)
Tumour (All) 12 28 27 13
p = 0.12 (Fishers Exact Test) p = 0.005* (Fishers Exact Test)
A comparison of FGFR2 staining in normal tissue and tumour tissue. The analysis is performed twice, firstly for a cut-off of 0 (no staining), and secondly for
staining scores of 4 or greater. Initially the analysis was performed using data from the 29 cases where both tumour and normal tissue were present in the same
slide. Subsequently, we also repeated the analysis using data from all 40 tumours compared to the 29 normal tissues that could be scored. When using a cut-off
of 4, the first analysis showed marginal significance using a Fishers exact test, with a higher level of significance seen if all the data was included. This suggests
increased FGFR2 staining in a proportion of tumours compared to normal tissue.
Table 3 A comparison of FGFR2 staining with oestrogen and progesterone receptor status of tumours
Nuclear Score 0 Nuclear Score
>0
Nuclear Score
0-3
Nuclear Score
4+
ER +ve 9 13 17 5
ER -ve 4 14 10 8
p = 0. 36 (Fishers Exact Test) p = 0.26 (Fishers Exact Test)
PR +ve 4 10 10 4
PR -ve 8 17 16 9
p = 1.0 (Fishers Exact Test) p = 0.92 (Fishers Exact Test)
No significant difference in FGFR2 staining was seen with hormonal status of tumours.
Table 5 A comparison of FGFR2 staining between tumour
and adjacent normal tissue within the same slide
Nuclear Score of Adjacent Normal
Tissue
0> 0
Tumour Nuclear Score 0 10 1
>0 5 13
P = 0.002 (Fishers Exact test)
§ Nuclear Score of Adjacent Normal Tissue
0-3 4+
Tumour Nuclear Score 0-3 21 1
4+ 7 0
P = 1 (Fishers Exact test)
A comparison of nuclear staining for FGFR2 within each slide for the 29
samples where normal and tumour tissue was available on the same slide.
The first analysis used a cutoff of staining against no staining. In most cases,
where staining was present in the normal tissue, this was reflected in the
adjacent tumour. In 5 cases, tumour staining was seen where staining of
adjacent normal tissue was not, and in only one case did staining appear to
be lost in tumour. Repeating this analysis as before, using a cutoff of 4, the
analysis was not significant, as only a single normal tissue stained to this
level.
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cancer, and its relationship to genotype is complex.
More studies are required to understand how the low-
penetrance breast cancer risk polymorphisms in
FGFR2 act to confer this risk, and how this informa-
tion can be used to improve breast cancer prevention
or treatment.
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